HIV/AIDS Drugs: April 2007 Archives

Key Hearing Awaits Pfizer Drug

|

pfizerA panel of outside medical experts is meeting Tuesday to evaluate a Pfizer HIV and AIDS drug that, if approved, would the the first in a new class of treatments. Pfizer is seeking support from the Food and Drug Administration for maraviroc, a pill being targeted at patients for whom other drugs, or drug combinations, have become ineffective.

Maraviroc "could broaden the arsenal of treatments to combat resistant forms" of the virus that causes AIDS, Pfizer told analysts last week when it issued first-quarter results. Maraviroc would be the first new oral class of HIV, or human immunodeficiency virus, medicines in more than 10 years, Pfizer said.

About this Archive

This page is a archive of entries in the HIV/AIDS Drugs category from April 2007.

HIV/AIDS Drugs: March 2007 is the previous archive.

Find recent content on the main index or look in the archives to find all content.

Pages

Powered by Movable Type 4.24-en